全文获取类型
收费全文 | 239724篇 |
免费 | 65461篇 |
国内免费 | 2628篇 |
专业分类
耳鼻咽喉 | 6084篇 |
儿科学 | 9457篇 |
妇产科学 | 3876篇 |
基础医学 | 20969篇 |
口腔科学 | 6723篇 |
临床医学 | 39189篇 |
内科学 | 71085篇 |
皮肤病学 | 14374篇 |
神经病学 | 26720篇 |
特种医学 | 8716篇 |
外国民族医学 | 1篇 |
外科学 | 55765篇 |
综合类 | 934篇 |
现状与发展 | 74篇 |
一般理论 | 27篇 |
预防医学 | 11532篇 |
眼科学 | 4810篇 |
药学 | 7872篇 |
中国医学 | 1178篇 |
肿瘤学 | 18427篇 |
出版年
2024年 | 695篇 |
2023年 | 4907篇 |
2022年 | 1573篇 |
2021年 | 4946篇 |
2020年 | 11298篇 |
2019年 | 13197篇 |
2018年 | 16089篇 |
2017年 | 17215篇 |
2016年 | 18758篇 |
2015年 | 18932篇 |
2014年 | 25996篇 |
2013年 | 26852篇 |
2012年 | 10327篇 |
2011年 | 10341篇 |
2010年 | 18734篇 |
2009年 | 19058篇 |
2008年 | 8565篇 |
2007年 | 5951篇 |
2006年 | 8408篇 |
2005年 | 5453篇 |
2004年 | 4583篇 |
2003年 | 3394篇 |
2002年 | 3507篇 |
2001年 | 5186篇 |
2000年 | 4289篇 |
1999年 | 3991篇 |
1998年 | 3858篇 |
1997年 | 3646篇 |
1996年 | 3508篇 |
1995年 | 3336篇 |
1994年 | 2054篇 |
1993年 | 1658篇 |
1992年 | 1715篇 |
1991年 | 1714篇 |
1990年 | 1345篇 |
1989年 | 1427篇 |
1988年 | 1266篇 |
1987年 | 1079篇 |
1986年 | 1081篇 |
1985年 | 889篇 |
1984年 | 686篇 |
1983年 | 635篇 |
1982年 | 573篇 |
1981年 | 462篇 |
1980年 | 430篇 |
1979年 | 408篇 |
1978年 | 412篇 |
1977年 | 459篇 |
1975年 | 349篇 |
1972年 | 391篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
5.
6.
7.
8.
9.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
10.